Pharmacokinetics of lisuride after subcutaneous infusion
Six parkinsonian patients received a constant subcutaneous infusion of 60 µg lisuride per hour in the abdominal region for 2 hours. Plasma levels of the unchanged drug were measured by radio-immunoassay. During infusion, a steady state plasma level of 0.78 ± 0.19ng/ml was achieved. After discontinuation of the infusion, concentrations declined with a half-life of 1.4 ± 0.4 hour. The total clearance of lisuride was 20 ± 6 ml/min/kg. Due to the low interpatient variability of plasma levels, a good control of clinical effects is to be expected.
KeywordsPlasma Level Total Clearance Unchanged Drug Parkinsonian Patient Abdominal Region
Unable to display preview. Download preview PDF.
- Dorow R, Gräf KJ, Nieuweboer B, Horowski R (1980) Intravenous lisuride: a new tool for testing responsiveness to dopamine agonists and neuroendocrine function. Acta Endocrinol [Suppl] (Copenh) 234: 9Google Scholar
- Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Clinical results using different modes of administration. J Neural Transm [Suppl] 27: 27–33Google Scholar
- Suchy I, Horowski R (1984) Use of the ergot derivative lisuride in Parkinson’s disease. In: Bergmann KJ (eds) Advances in neurology, vol 40. Raven Press, New York, p 561–568Google Scholar
- Luquin MR, Obeso JA, Martinez-Lage MJ, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1986) Parenteral administration of lisuride in Parkinson’s disease. In: Baker MD, Hassler RG (eds) Advances in neurology, vol 45. Raven Press, New York, p515–521Google Scholar